Carcinoma basocelular agresivo del párpado inferior: ventaja del vismodegib neoadyuvante

Monteiro, AF; Rato, M; Trigo, M; Martins, C.
Actas dermo-sifiliogr. (Ed. impr.) ; 110(10): 863-865, dic. 2019. ilus
Artigo em Espanhol | IBECS (Espanha) | ID: ibc-185613

Documentos relacionados

  1. Can the Safe Surgical Margin Be Narrowed in Early-Stage Facial Basal Cell Carcinoma?
  2. Vismodegib as Eye-Sparing Neoadjuvant Treatment for Locally Advanced Periocular Basal Cell Carcinoma.
  3. The Role of Surgery After Remission of Nonsystemic Extensive Periorbital Basal Cell Carcinoma Treated by Vismodegib: A Systematic Review.
  4. Surgery Alone (Without Adjuvant Radiation) Adequately Treats Histologic Perineural Basal Cell Carcinomas: A Systematic Review With Meta-Analysis.
  5. Reply to "Local recurrence of clinically observed basal cell carcinoma…".
  6. Therapy Failure and Resistance Mechanism in Eyelid and Ocular Surface Tumors.
  7. Recurrent Deeply Invasive Basal Cell Carcinoma.
  8. Curettage vs. cryosurgery for superficial basal cell carcinoma: a prospective, randomised and controlled trial.
  9. Results of Mohs' Micrographic Surgery of Periocular Basal Cell Carcinoma: The Swedish Experience.
  10. Basal Cell Carcinoma of the Head and Neck-A Retrospective Single-Centre Comparison of the Recurrence Rate after R0 or R1 Resection.